Results 171 to 180 of about 143,744 (251)

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, EarlyView.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Bioinformatics analyses reveal the role of RIPK1 in clear cell renal cell carcinoma. [PDF]

BMC Cancer
Fang D, Hu Y, Sun S, Wen H, Fan J.
europepmc   +1 more source

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

International Journal of Cancer, EarlyView.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley, Liesbet J. Van Eycken, Meredith E. Giuliani, Brian A. Rous, Shao Hui Huang, Hisao Asamura, Mary K. Gospodarowicz, Anne W. Lee, Brian O'Sullivan   +8 more
wiley   +1 more source

Pretreatment intratumoral mature TLSs in non-clear cell renal cell carcinoma are associated with response to immunotherapy rechallenge. [PDF]

J Immunother Cancer
Tang Y, Chen J, Hu J, Liu D, Ma K, Chen Y, Wang L, Zhang X, Hu X, Zhao J, Wang X, Guo J, Liu H, Zhao J, Wang Z, Xu N, He S, Wei X, Wang Y, Wang Z, Yao J, Chen N, Shen P, Liu Z, Sun G, Zeng H, Liang J.   +26 more
europepmc   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Comprehensive bioinformatics and experimental analysis of PPOX reveals its carcinogenic effect in clear cell renal cell carcinoma. [PDF]

Transl Androl Urol
Wang K, Wang L, Zhang Y, Hou D, Kang L, Qin Z, Zhu X, Li C, Wang H.   +8 more
europepmc   +1 more source

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients

International Journal of Cancer, EarlyView.
Long non‐coding RNAs (lncRNAs) signatures are promising cancer biomarkers, since their dysregulation in tumors is reflected in body fluids. In this study, next‐generation sequencing, bioinformatics, and gene expression data were combined to investigate an lncRNA signature linked specifically to the cancer‐promoting YAP in several cancer types ...
Fabian Rose, Nada El‐Ekiaby, Lilija Wehling, Sofia Maria Elisabeth Weiler, Jennifer Schmitt, Marcell Tóth, Fabiola Pedrini, Amruta Damle‐Vartak, Carsten Sticht, Rossella Pellegrino, Injie Omar Fawzy, Merna Hatem Mohamed Hamad, Mohamed Negm, Dina Omar, Hossam Eldeen Soliman, Gamal Esmat, Thomas Longerich, Thomas Illig, Bruno Christian Köhler, Anna Saborowski, Heike Bantel, Arndt Vogel, Peter Schirmacher, Ahmed Ihab Abdelaziz, Kai Breuhahn   +24 more
wiley   +1 more source

UBE2C contributes to malignant phenotypes in clear cell renal cell carcinoma <i>via</i> cell cycle and apoptosis regulation. [PDF]

PeerJ
Qin T, Liang J, Ya W, Long Y, Wu J, Meng D, Gan F.   +6 more
europepmc   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source